Eph receptor A2 (EPHA2) Human Recombinant Protein
CNY 3,140.00
货期*
5周
规格
Product images
经常一起买 (1)
Specifications
Product Data | |
Species | Human |
Protein Source | Human 293 |
Expression cDNA Clone or AA Sequence |
Ala24-Asn534
|
Tag | C-hFc |
Buffer | Lyophilized from a 0.2 um filtered solution of PBS, pH 7.4 |
Note | Recombinant Human EphA2 is produced by our Mammalian expression system and the target gene encoding Ala24-Asn534 is expressed with a hFc tag at the C-terminus. |
Storage | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-5 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
Stability | 12 months from date of despatch |
Reference Data | |
Locus ID | 1969 |
UniProt ID | P29317 |
Synonyms | Ephrin type-A receptor 2; Epithelial cell kinase; Tyrosine-protein kinase receptor ECK; EPHA2 |
Summary | Ephrin type-A receptor 2 (EphA2) belongs to the Eph receptor tyrosine kinase family which binds Ephrins A1, 2, 3, 4, and 5. The ephrins and Eph receptors are implicated as positional labels that may guide the development of neural topographic maps. They have also been found involved in embryonic patterning, neuronal targeting, vascular development and adult neovascularization. Furthermore, elevated expression of Eph receptors and ephrin ligands is associated with tumors and associated tumor vasculature, suggesting the Eph receptors and ephrin ligands also play critical roles in tumor angiogenesis and tumor growth. EphA2 is upregulated in breast, prostate, and colon cancer vascular endothelium. Its ligand, EphrinA1, is expressed by the local tumor cells. In some cases, EphA2 and EphrinA1 are expressed in the same blood vessels. EphA2 signaling cooperates with VEGF receptor signaling in promoting endothelial cell migration. |
Protein Families | Druggable Genome, Protein Kinase, Transmembrane |
Protein Pathways | Axon guidance |
Documents
FAQs |
SDS |
其它Eph receptor A2产品
Customer
Reviews
Loading...